Letrozole-ınduced very early systemic sclerosis in a patient with breast cancer: A case report

Aromatase inhibitors (AIs) are standard therapy for post-menopausal women with breast cancer. The use of AIs has been strongly associated with musculoskeletal symptoms and with various autoimmune conditions recently. Systemic sclerosis (SSc) is a connective tissue disorder of unknown etiology which may present with a broad range of clinical manifestations. In SSc, matrix deposition by activated fibroblasts leads to vasculopathy, systemic fibrosis, and end-organ damage. Skin, kidneys, pulmonary and gastrointestinal systems may be affected. Very early SSc can be diagnosed in patients with Raynaud’s phenomenon and puffy fingers as well as through autoantibodies and nailfold capillaroscopy. These symptoms are highly predictive of the further development of definite SSc. In this article, we report an unusual case of a 61-year-old female breast cancer with a very early-onset SSc with bilateral stiffness of the hands, Raynaud’s phenomenon, puffy fingers, dilated nailfold capillaries and positive anticentromere-B antibody titers after undergoing AI therapy with letrozole. Substitution of letrozole with exemestane followed by eventual discontinuation of AI therapy appears to relieve symptoms. To the best of our knowledge, this is the first report suggesting a link between AI use and SSc. We suggest that AI use may induce SSc, or at least, exacerbate existing very early SSc in post-menopausal patients with breast cancer.


1. Adelson K, Germain D, Raptis G, Biran N. Hormonal modulation in the treatment of breast cancer. Endocrinol Metab Clin North Am 2011;40:519–32.

2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557–67.

3. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246–55.

4. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011;70:476–81.

5. Salgado BA, Zivian MT. Aromatase inhibitors: side effects reported by 622 women. Breast Cancer Res Treat 2006;100:S168.

6. Santoro S, Santini M, Pepe C, Tognetti E, Cortelazzi C, Ficarelli E, et al. Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. J Eur Acad Dermatol Venereol 2011;25:596–8.

7. Trancart M, Cavailhes A, Balme B, Skowron F. Anastrozole-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2008;158:628–9.

8. Bertolini E, Letho-Gyselinck H, Prati C, Wendling D. Rheumatoid arthritis and aromatase inhibitors. Joint Bone Spine 2011;78:62–4.

9. Laroche M, Borg S, Lassoued S, De Lafontan B, Roché H. Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome. J Rheumatol 2007;34:2259–63.

10. Inno A, Basso M, Vecchio FM, Marsico VA, Cerchiaro E, D’Argento E, et al. Anastrozole-related acute hepatitis with autoimmune features: a case report. BMC Gastroenterol 2011;11:32.

11. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5.

12. Haustein UF, Haupt B. Drug-induced scleroderma and sclerodermiform conditions. Clin Dermatol 1998;16:353–66.

13. Böni R, Dummer R, Burg G. Acral sclerosis and leukoderma in a melanoma patient treated with interferon alpha and interleukin-2. Eur J Dermatol 1995;5:383–5.

14. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58:3902–12.

15. Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, et al. Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2013;52:143–54.

16. Marasini B, Conciato L, Belloli L, Massarotti M. Systemic sclerosis and cancer. Int J Immunopathol Pharmacol 2009;22:573–8.

17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.

Kaynak Göster

1405 957

Sayıdaki Diğer Makaleler

R: Avascular necrosis of the femoral head in a patient with behçet's disease

Hatice Tuba SANAL

Inspection of endothelial nitric oxide synthase gene polymorphism in patients with henoch schönlein purpura


Clinical manifestations of neuropsychiatric systemic lupus erythematosus in chinese patients

Wei FAN, Zhenyuan ZHOU, Liangjing LU, Shunle CHEN, Chunde BAO

Function of the ınfrapatellar fat pad and advanced hoffa's disease with ossification


Expression of survivin in patients with refractory rheumatoid arthritis in a chinese population

Xian Ming LONG, Jinwei CHEN, Wen Jing WANG, Jia WANG

Letrozole-ınduced very early systemic sclerosis in a patient with breast cancer: A case report


The chartographer of hysteria and fibromyalgia tender points

Franceco BRIGO

Coexistence of ankylosing spondylitis with morphea: A case report

Kevser GÜMÜŞSU, Aylin REZVANİ, Nihal ÖZARAS, Mustafa GÜLER, Özlem SU

Wegener's granulomatosis presenting with an ısolated paranasal sinus ınvolvement in a child

Ghaniya DAAR, Ali Bülent CENGİZ, Ateş KARA, Rezan TOPALOĞLU, Ömer Taşkın YÜCEL, İsmail DURSUN

Mediterranean fever gene mutations and messenger ribonucleic acid expressions in pediatric patients with familial mediterranean fever in the Trakya region of Turkey